Peer Review History

Original SubmissionAugust 29, 2022
Decision Letter - Ferdinando Carlo Sasso, Editor

PONE-D-22-24140Prevalence and Associated Factors of Visual Impairment Among Adult Diabetic Patients Visiting Adare General Hospital, Hawassa, South Ethiopia, 2022PLOS ONE

Dear Dr. Tilahun,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:

Please submit your revised manuscript by Oct 27 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ferdinando Carlo Sasso, PhD, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter

Additional Editor Comments:

The reviewers raised several issues about discussion section and study limitations.

Please, address all issues raised by the reviewers and submit a revised manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I read with great interest the paper “Prevalence and Associated Factors of Visual Impairment Among Adult Diabetic Patients Visiting Adare General Hospital, Hawassa, South Ethiopia, 2022" by Mikias Mered Tilahun et al.

The article is well written. Paper design is fine. The article is logically divided into sections and subsections. The analysis is well performed

Comments:

1. Limitation of the study is also represented by the lack of data about 2 major risk factors that have been associated to diabetic retinopathy, that are albuminuric chronic kidney disease and high HDL levels, which should be added to the appropriate section.

2. Discussion should be treated more in depth. For example, the role played by physical activity in ameliorating insulin resistance. In fact, a wrong lifestyle may produce an excessively positive caloric balance, thus causing insulin resistance by enhancing visceral adipose tissue and consequently releasing a much higher level of free fatty acids, TNF-α, adipokines and hyperglycaemia which will lead to increased inflammation, endothelial disfunction and, as a consequence to increased prevalence of diabetes complications and in particular retinopathy (doi: 10.3390/antiox10020270).

Reviewer #2: Dear Editor

I’ve read with great interest the manuscript draft “Prevalence and Associated Factors of Visual Impairment Among Adult Diabetic Patients Visiting Adare General Hospital, Hawassa, South Ethiopia, 2022” by Henok Biruk Alemayehu et al. However, some issues need to be raised.

Abstract:

- There are some typing errors.

Introduction:

- “Diabetes is a complex…” seems too generic, I would suggest to specify which type of diabetes.

- Please insert the entire words when an acronym is used for the first time throughout the text.

Methods:

- The authors write “systemic co-morbidities were collected from each patient's medical chart”. I would suggest to briefly specify how co-morbidities diagnosis has been done, particularly for what concerns the statistically associated peripheral neuropathy.

Discussion:

- The authors write “Studying the prevalence in this setup would increase the magnitude of visual impairment.” Recently, some authors have demonstrated that telemedicine could allow to implement the screening programs also during a pandemic period (Galiero R, Pafundi PC, Nevola R, et al. The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy. J Diabetes Res. 2020;2020:9036847. Published 2020 Oct 14. doi:10.1155/2020/9036847; Sasso FC, Pafundi PC, Gelso A, et al. Telemedicine for screening diabetic retinopathy: The NO BLIND Italian multicenter study. Diabetes Metab Res Rev. 2019;35(3):e3113. doi:10.1002/dmrr.3113). I would suggest to briefly discuss this point.

Limitations:

- This is a single-center study, thus it seems difficult to fully generalize the results. I would suggest to add this issue to limitations section.

- To evaluate glycemic control, the study lacks glycated hemoglobin, I would suggest to discuss this issue or to move in to limitation section.

Conclusion:

- The authors write “Diabetic patients should engage in regular physical activity for at least 150 minutes per week, control their glucose levels with proper use of medication, and have regular eye

exams.”, however no references have been associated with this sentence. I would suggest to at least a reference linked to this point.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Point by point response to reviewer`s comment

Manuscript title: Prevalence and Associated Factors of Visual Impairment Among Adult Diabetic Patients Visiting Adare General Hospital, Hawassa, South Ethiopia, 2022

Manuscript number:

Dear Reviewer. Thank you for providing us the chance to revise our manuscript. We are great full for your careful and in-depth reading of the manuscript. We appreciate your thoughtful comments and constructive suggestions, which help us to improve the quality of the manuscript. Having this we addressed all the concerns raised and incorporated our reflections in the revised manuscript. We attempted to address all the issues raised to be corrected.

Many thanks

Responses to Reviewers

Reviewer- 1

1. Reviewer’s comment: Limitation of the study is also represented by the lack of data about 2 major risk factors that have been associated to diabetic retinopathy, that are albuminuric chronic kidney disease and high HDL levels, which should be added to the appropriate section.

Authors’ response: Thank you for your comment. We accept the comment and made necessary correction in the revised manuscript.

2. Reviewer’s comment: Discussion should be treated more in depth. For example, the role played by physical activity in ameliorating insulin resistance. In fact, a wrong lifestyle may produce an excessively positive caloric balance, thus causing insulin resistance by enhancing visceral adipose tissue and consequently releasing a much higher level of free fatty acids, TNF-α, adipokines and hyperglycaemia which will lead to increased inflammation, endothelial disfunction and, as a consequence to increased prevalence of diabetes complications and in particular retinopathy (doi: 10.3390/antiox10020270).

Authors’ response: Thank you for your depth insight. We accept it and made incorporated this relevant information with in the revised manuscript.

Reviewer - 2

1. Reviewer’s comment: Abstract: There are some typing errors.

Authors’ response: Thank you for your comment. We accept the comment and made necessary correction in the revised manuscript

2. Reviewer’s comment: Introduction: “Diabetes is a complex…” seems too generic, I would suggest to specify which type of diabetes.

Authors’ response: Thank you for your suggestion. We accept it and we tried to address your suggestion in the revised manuscript

But diabetes both type I and II were found resulted hyperglycemia with different mechanism.

3. Reviewer’s comment - Please insert the entire words when an acronym is used for the first time throughout the text

Author response: Thank you for your comment. We made correction within the revised manuscript

4. Reviewer’s comment: Methods - The authors write “systemic co-morbidities were collected from each patient's medical chart”. I would suggest to briefly specify how co-morbidities diagnosis has been done, particularly for what concerns the statistically associated peripheral neuropathy.

Author response: Thank for your comment. We accept the insight and include the clinical diagnostic criteria of peripheral neuropathy in the revised manuscript. Even though here were the diagnosis criteria of other systemic co morbidities included in our study Diagnosis of hypertension was made based on patients’ blood pressure when a person's systolic blood pressure is ≥140 mm Hg and/or their diastolic blood pressure ≥90 mm Hg following repeated examination. Anemia was diagnosed based on laboratory results of blood hemoglobin concentration (below 130 g/L for men, 120 g/L for females). Heart disease and nephropathy were diagnosed by their respective clinics, and patients were already on their medication. Peripheral neuropathy was diagnosed based on a person’s medical history and physical examination (inspection of feet, vibration perception, ankle reflex test, and monofilament test)

5. Reviewer’s comment: Discussion: The authors write “Studying the prevalence in this setup would increase the magnitude of visual impairment.” Recently, some authors have demonstrated that telemedicine could allow to implement the screening programs also during a pandemic period (Galiero R, Pafundi PC, Nevola R, et al. The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy. J Diabetes Res. 2020;2020:9036847. Published 2020 Oct 14. doi:10.1155/2020/9036847; Sasso FC, Pafundi PC, Gelso A, et al. Telemedicine for screening diabetic retinopathy: The NO BLIND Italian multicenter study. Diabetes Metab Res Rev. 2019;35(3):e3113. doi:10.1002/dmrr.3113). I would suggest to briefly discuss this point.

Author response: Thank you for your suggestion. We accept it and we tried to show the impact of Telemedicine for screening diabetic retinopathy on reduction of visual impairment among patients with diabetes.

6. Reviewer’s comment: Limitations - This is a single-center study, thus it seems difficult to fully generalize the results. I would suggest adding this issue to limitations section.

- To evaluate glycemic control, the study lacks glycated hemoglobin, I would suggest to discuss this issue or to move in to limitation section.

Authors’ response: Thank you for your comment. We accept the comment and made necessary correction in the new revised manuscript.

7. Reviewer’s comment: Conclusion:

- The authors write “Diabetic patients should engage in regular physical activity for at least 150 minutes per week, control their glucose levels with proper use of medication, and have regular eye exams.”, however no references have been associated with this sentence. I would suggest to at least a reference linked to this point

Author response: Thank you for your critical insight. But in this study, poor physical exercise, poor glucose control and having no history of eye examination were significantly associated with visual impairment. Based on this fining, we have recommend that those patient with diabetes should engage in regular physical activity for at least 150 minutes per week, control their glucose levels with proper use of medication, and have regular eye exams. So, we believed that no need of referencing.

Attachments
Attachment
Submitted filename: Reviewer respoonse.docx
Decision Letter - Ferdinando Carlo Sasso, Editor

Prevalence and Associated Factors of Visual Impairment Among Adult Diabetic Patients Visiting Adare General Hospital, Hawassa, South Ethiopia, 2022

PONE-D-22-24140R1

Dear Dr. Tilahun,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ferdinando Carlo Sasso, PhD, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The authors addressed all issues raised by reviewers.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors answered appropriately to all my quarries. The paper can now be further processed for publication

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Ferdinando Carlo Sasso, Editor

PONE-D-22-24140R1

Prevalence and Associated Factors of Visual Impairment Among Adult Diabetic Patients Visiting Adare General Hospital, Hawassa, South Ethiopia, 2022

Dear Dr. Tilahun:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Ferdinando Carlo Sasso

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .